05/14/2026
GLP-1 MEDICATIONS
GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally produced in the gut that regulates blood sugar levels, slows gastric emptying (digestion), and signals fullness to the brain.
Natural Function: Released after eating, it stimulates insulin secretion and suppresses glucagon to manage blood sugar.
Medication Use (GLP-1 Agonists): Popular medications like Ozempic, Wegovy, Mounjaro, and Zepbound are "GLP-1 receptor agonists". They mimic this natural hormone to treat type 2 diabetes and promote significant weight loss by curbing appetite.
Appetite Control: They increase feelings of satiety, helping people feel fuller for longer. GIP (glucose-dependent insulinotropic polypeptide) is another, similar gut hormone often paired with GLP-1 in newer, highly effective weight-loss medications (tirzepatide).
BENEFITS:
1. Weight Loss - https://pubmed.ncbi.nlm.nih.gov/41547366/
2. Reduction of major adverse cardiovascular events by 20% (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?utm_source=openevidence)
3. Improvements in heart failure, metabolic-associated steatohepatitis, osteoarthritis, chronic kidney disease in patients with type-2 diabetes, and prediabetes (https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70167).
4. Treatment of type-2 diabetes (https://www.epocrates.com/online/diseases/24/type-2-diatetes-ettitus-in-adults)
ADVERSE EFFECTS (4-7% of patients in clinical trials discontinued these medications due to adverse effects - https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024):
1. About 35% of weight loss is due to muscle loss (https://www.acpjournals.org/doi/10.7326/ANNALS-25-00478).
2. Gastrointestinal adverse events, including nausea, vomiting, abdominal pain, diarrhea, and constipation. This occurred in 47-84% of treated patients vs. 13-63% with placebo (https://pubmed.ncbi.nlm.nih.gov/39761578/). GI adverse effects are generally mild-to-moderate, dose-dependent, and tend to occur during dose escalation (https://www.sciencedirect.com/science/article/pii/S0002916525002400?via%3Dihub). Slowly increasing the dose helps minimize intolerance (https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024).
3. Less common adverse effects include gallbladder disease, pancreatitis, gastroparesis and bowel obstruction, and nonarteritic anterior ischemic optic neuropathy (https://pubmed.ncbi.nlm.nih.gov/41351656/).
CONTRAINDICATIONS (https://www.epocrates.com/online/drugs/7978/ozempic -dosing):
1. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (types of cancer)
2. Known hypersensitivity
3. GLP-1 medications have not been shown to be associated with suicidality (https://www.epocrates.com/online/contextuallink/article/study-probes-neuropsychiatric-outcomes-of-semaglutide-use)
*Ozempic (semiglutide) and Mounjaro (tirepatide) are FDA-approved only for type-2 diabetes.